- Completed
NCT02495922: Phase 3 - Elotuzumab in VRD Induction /Consolidation and Len maint in NDMM(GMMG-HD6)
Updated: Sep 15, 2022
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG-HD6)
German-speaking myeloma multicenter group
(GMMG)

Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment.
Sponsor
University of Heidelberg Medical Center
Information provided by (Responsible Party)
Prof. Dr. Hartmut Goldschmidt, University of Heidelberg Medical Center
German Study
ClinicalTrials.gov Identifier: NCT02495922
Official Title: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma